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Aim: To characterize sequence variations in the ANK gene in fam- 
ilies with autosomal dominant CPPDD. 
Methods and Results: Analyses included screening for 
sequence variants in all 12 exons, including intron/exon splice 
junctions, as well as analysis of 200 bp of the 5'UTR region. Also, 
Southern blot analyses were performed to detect major deletions, 
re-arrangements, or insertions of the gene, and quantitative RT- 
PCR was utilized to determine relative levels of expression of 
AINK transcripts in fibrobiasts from affected family members ver- 
sus controls. Numerous sequence variants were detected in ANK; 
these included exon and intron SNPs, as well as a SNP in the 5' 
UTR region of the gene. In one family, a heterozygous base sub- 
stitution in exon 1 changed a proline to threonine at position 5; 
however, this variant did not occur on the disease haplotype, 
suggesting that it is a polymorphism that is not associated with 
the disease in this family. There was no evidence of a major gene 
defect, and analysis of expression levels for ANK in our families 
was unremarkable. 
Conclusions: Familial CPPDD is a genetic disorder of articular 
cartilage that is characterized by the deposition of calcium-con- 
taining crystals in affected joints. Genetic analyses of numerous 
families whose CPPDD segregates as a dominant rait have iden- 
tiffed a locus (CCAL2) on the short arm of chromosome 5 that 
harbors a gone that is responsible for the disease. There are sev- 
eral positional candidates in the CPPDD chromosome 5p interval, 
including ANK, the human homolog of the mouse progressive 
ankylosis (ank) gene. ANK codes for an integral membrane pro- 
tein that acts as a transmembrane transporter for inorganic 
pyrophosphate (PPi). In recessive ank/ank mice, loss of ank activ- 
ity apparently leads to a drop in extracellutar PPi levels, resulting 
in unregulated apatite calcification in joints. In light of the numer- 
ous reports of anomalous regulation of PPi metabolism in 
patients with CPPDD, we undertook characterization of ANK in 
our 5p CPPDD families. Our observations uggest that ANK is not 
the gene responsible for CPPDD in these families. However, 
information with regard to polymorphisms inthis gene will be use- 
ful in future studies of genetic association and linkage disequilib- 
rium. 
(Supported by AR44360 to C.J.W.) 
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ADENOVIRAL OVEREXPRESSION OF SMAD-7 COMPLETELY 
BLOCKS TRANSFORMING GROWTH FACTOR-~ ACTIVITY IN 
CULTURED CHONDROCYTES 
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Aim: To assess whether overexpression of Smad-6 and -7 
blocks TGF-13 activity in cultured chondrocytes. 
Methods: Bioactivity of Smad-6 and -7 was determined via the 
ability to block TGF-[] responses on a TGF-~ sensitive cell line 
(MLEC). Chondrocytes were transfected with adenoviruses con- 
taining the gene encoding Smad-6, -7 or luciferase or were not 
transfected. Transfected cells were stimulated for 48 hours with 
TGF-I~ and compared to unstimulated cells. The effect of Ad- 
Smad-6 and -7 on chondrocyte proliferation (DNA content) and 
PG synthesis (35S incorporation) was studied. Protein expression 
of Smad-7 was performed via immunocytochemistry using an 
anti-Smad-7Ab. Expression levels of Smad-6, -7 and aggrecan 
were examined by semi-quantitative RT-PCR. 
Results: Ad-Smad-7 was able to inhibit 95.5% of TGF-~ 
induced luminescence in the MLEC cells, whereas Ad-Smad-6 
only inhibited TGF-I~ responses for 25%. Transfection of chon- 
drocytes with Ad-Smad-6 or -7 upregulated mRNA for Smad-6 
110 times and Smad-7 357 times, respectively, compared with 
Ad-luciferase. On the protein level, Smad-7 was readily detected 
in chondrocytes transfected with Ad-Smad-7 and not in any of 
the control treated cells. Smad-6 protein expression could not be 
determined because of nonspecificity of the antibody. As expect- 
ed, TGF-~ induced an increase in chondrocyte cell number, which 
could be completely inhibited by Ad-Smad-7 only. Moreover, the 
increase in PG synthesis induced by TGF-~ (corrected for cell 
number) could be blocked for 90% by Ad-Smad-7 and for 47% 
by Ad-Smad-6 and not by Ad-luciferase. The TGF-~ induced 
upregulation of aggrecan on the mRNA level could be complete- 
ly blocked with Ad-Smad-7 but not with Ad-Smad-6 or Ad- 
luciferase. 
Conclusions: The TGF-13 family uses receptor-associated 
Smads and the common mediator Smad-4 to transduce its signal 
to the nucleus. Smads-6 and -7 are strongly implied in the inhibi- 
tion of the TGF-I3 family signaling pathway. We tested the feasi- 
bility of Smad-6 and -7 as possible TGF-~ inhibitors in chondro- 
cytes. Smad-6 incompletely blocked TGF-I~ effects on MEEC 
cells and on PG synthesis and is therefore only a partial inhibitor 
for TGF-~ in chondmcytes. In contrast, Smad-7 could fully inhib- 
it all TGF-~ induced responses in chondrocytes we investigated. 
We conclude that Smad-7 is a very potent TGF-~ antagonist and 
that Ad-Smad-7 is a powerful tool to study TGF-~ effects in vivo. 
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To identify patterns of gene expression products that are specifi- 
cally regulated in osteoarthritis (OA) compared with rheumatoid 
arthritis (RA) and the healthy state (ND), gene expression was 
monitored by subtractive hybridization with representational dif- 
ference analysis (RDA), and by complex hybridizations on cDNA 
chips. RDA was performed by subtracting OA from RA represen- 
tations and ND from OA representations. The difference-products 
were selectively amplified, cloned, sequenced and compared to 
published sequences in the Genebank. - Microarray hybridiza- 
tions were carried out using arrayed cDNA tags (Affymetrix) of 
approx. 60,000 genes. Differential expression of identified genes 
was validated by semiquantitative RT-PCR. Approximately 100 
genes were found to be differentially expressed in OA synovial 
tissue compared to ND tissues. Genes of highest regulation were 
associated with leukocyte activation (3" cells antigens, sema- 
phorine, cell surface proteins), with tissue destruction and remod- 
eling (MMP-1, BMP-3b), and extracellular matrix components 
(integrins, fibronectin). Interestingly, a large set of genes was 
found downregulated in BA and OA, such as members of the 
TGF-b superfamily, apoptosls associated molecules or transcrip- 
tion factors. Beside genes already described as relevant in the 
pathogenesis of OA, others have not been assigned to this back- 
ground, yet. Profiles of differentially expressed genes obtained by 
microarrays are overlapping with those obtained by subtractive 
hybridizations. The validity of either technique was confirmed by 
semiquantitative RT-PCR. Thus, a pattern of genes was generat- 
ed, which is preferentially expressed in OA. Such patterns could 
be of diagnostic value and contribute to the characterization of 
the pathogenesis of chronic joint diseases. 
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In healthy articular cartilage chondrocytes remain a stable phe- 
notype and maintain their extraceltular matrix. In osteoarthritis 
(OA), however, very little is known about he fate of articular chon- 
drocytes during the progression of the disease. Previously we 
have shown that chondrocytes in the upper zone of OA cartilage 
express markers of hypertrophy and undergo apoptotic changes 
(Kirsch eta., 2000 Osteoarthritis & Cartilage 8:294-302). In this 
study, we examined the expression of syndcan-3, a marker of 
early chondrocyte differentiation, and annexin VI, a marker of late 
chondrocyte differentiation, in embryonic growth plate cartilage 
and normal and OA human articular cartilage. While syndecan 3 
was exclusively expressed in the proliferative zone of growth 
plate cartilage, annexin VI immunostaining was restricted to the 
hypertrophic and mineralizing zones of growth plate cartilage. 
Approximately 20% of chondrocytes were immunopositive for 
syndecan 3 in normal human articular cartilage, the number of 
syndecan 3-expressing chondrocytes increased to more than 
80% of cells in the upper zone of severely affected OA cartilage. 
Similarly, the number of annexin VI and alkaline phosphatase- 
expressing cells significantly increased in the upper cartilage 
zone during the progression of OA. Double labeling experiments 
with antibodies against syndecan 3 and annexin VI revealed 
chondrocytes, which expressed only syndecan 3, and cells which 
expressed both syndecan 3 and annexin VL These results indi- 
cate that the expression of early (syndecan 3) and late differenti- 
ation markers (annexin Vl, alkaline phosphatase) is activated in 
chondrocytes of OA cartilage. 
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Aim of the study: To analyze the correlation of degenerative 
osteoarthritis with and without synovitis and CD44H, sCD44v5 
and sCD44v6 iso forms in knee joint synovial fluid. 
Material and Methods: Synovial fluid from 52 patients with dif- 
ferant grades of primary osteoarthritis of the knee joint with and 
without synovitis was collected during surgical procedures 
including arthroscopy or primary total knee arthroplasty. ELI SA- 
Kits CD44H, sCD44v5 and sCD44v6 were used to analyze the 
concentrations. 
Results: The osteoarthritis grading was in average 3.5 for 
Keltgren. The data distribution shows a decreased (not significant 
0.05) synovial concentration of all CD44 isoforms with higher 
osteoarthritis grading. All isoforms show higher synovial fluid lev- 
els in osteoarthritis and synovial inflammation than in osteoarthri- 
$35 
tis without synovitis (CD44H p=0.00035; CD44v5 p= 0.150 10; 
CD44v6 p=0.01337). Correlation between the Keligren score and 
CD44 values were found only for CD44v6. 
Conclusion: The catabolic effect on articular cartilage loss over 
time is clinically and radiologically represented in the grade of 
osteoarthritis, but altered CD44 isoform synovial fluid levels of the 
knee joint do not reflect a certain grade of knee osteoarthritis. 
Synovial inflammation of the human osteoarthritic knee joint is 
correlated with CD44H and CD44v6, but not with CD44v5 syn- 
ovial fluid levels. 
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SHORT TERM (1-YEAR) CHANGES IN KERATAN SULFATE 
LEVELS PREDICT LONG-TERM (3-YEAR) RADIOLOGICAL 
EVOLUTION OF KNEE OSTEOARTHRITIS IN PATIENTS 
TREATED WITH GLUCOSAMINE SULFATE 
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Background: With the emergence of effective structure-modify- 
ing treatments for ostecarthritis (OA), biochemical markers could 
be used to monitor response to therapy. 
Objective: To investigate whether baseline values and 1-year 
changes in biochemical markers of bone and cartilage turnover 
[serum osteocalcin (OC), urine PyridinoUne/Creatinine ratio (PYD), 
urine Deoxypyridinoline/creatinine ratio (DPD), serum hyaluronic 
acid (HA), serum keratan sulfate (KS), and serum cartilage 
oligomeric matrix protein (COMP)] predict the 3-year structural 
progression of knee OA in patient treated with glucosamine sul- 
fate. 
Methods: Data were derived from a cohort of 106 individuals cor- 
responding to the treated arm of a double-blind placebo-con- 
trolled trial having showed the role of 1500 mg of gtucosarnine 
sulfate as a disease-modifying drug in OA. Joint space width 
(JSW) of the medial compartment of the tibio-femoral joint was 
assessed by digital image analysis with a validated computerized 
algorithm (mean JSW) and with a graduated magnifying lens 
(minimal JSW). 
Results: No marker at baseline was correlated with the 3-year 
changes in mean or minimal JSW. However, the 1-year changes 
(values at 12-month - values at baseline) in KS were significantly 
correlated with 3-year changes in minimal JSW (r = 0.28, p = 
0.02). In patients with 1-year changes in KS above the median p 
34.7 ngE/ml), joint space increased over 3-year by [mean (SD)] 
0.35 (0.93) mm while patients with changes in KS below the value 
(1~ 34.7 ngE/ml) had a mean joint space narrowing of 0.16 (0.82) 
mm. Difference between the two groups is statistically significant 
(p = 0.02). 
Conclusion. We conclude that short-term (1 -year) changes in KS 
levels predict long-term (3-year) clinical and radiological evolution 
of knee osteoarthritis in patients treated with glucosamine sulfate. 
